Navigation Links
Decision Resources to Publish Reports That Include Market Analysis and a Forecast through 2022 for the Hepatitis C Virus and Hospital-Treated Bacterial Infections Drug Markets
Date:12/18/2013

BURLINGTON, Mass., Dec. 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, will soon publish a comprehensive market analysis and a forecast though 2022 for both the hepatitis C virus (HCV) drug market and the hospital-treated bacterial infections drug market.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Key findings from the upcoming Pharmacor advisory service entitled Hepatitis C Virus reveal that Gilead's Sovaldi—the first direct acting antiviral (DAA) approved for the treatment of HCV as part of an IFN-free regimen—represents a safe, convenient (all-oral), and highly efficacious option for genotype-1, -2 and -3 patients, particularly those who are unable or unwilling to undergo treatment with IFN-based regimens. Sovaldi, as well as Janssen/Medivir's Olysio/Sovriad, were both recently approved by the U.S. Food and Drug Administration for the treatment of both treatment-naive and treatment-experienced HCV patients.

The findings also reveal that the HCV pipeline is dynamic and competitive, owing to the large commercial potential that is well recognized by pharmaceutical developers. Agents in late-stage development—such as protease inhibitors (AbbVie's ritonavir-boosted ABT-450, Boehringer-Ingelheim's faldaprevir, Merck's MK-5172), polymerase inhibitors (AbbVie's ABT-333, Bristol-Myers Squibb's BMS-791325, Boehringer-Ingelheim's deleobuvir) and NS5A inhibitors (Bristol-Myers Squibb's daclatasvir, Gilead's ledipasvir and GS-5816, AbbVie's ABT-267 and Merck's MK-8742), among others—are expected to drive dramatic growth of the HCV market through 2022. These DAAs are being evaluated in all-oral, IFN-free regimens consisting of 2-3 DAAs in combinations with and without ribavirin.

Key findings from t
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. National Decision Support Company offers free access to ACR Select
2. Pharmspective Launches Affordable Care Act eLearning for Healthcare Decision-Makers
3. Pharmaceutical Industry Turning to Emerging Market Research Tools to Better Understand Consumer Decision-Making
4. Decision on State Exchanges Will Aid Patient Access to Medications
5. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
6. Beyond the Headlines: What the FDA Decisions on Extended-release and Long-Acting Opioids Mean for People With Pain
7. Strategic Insights Series Now Available from Decision Resources
8. Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
9. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
10. Hamilton Regional Laboratory Medicine Program Announces Decision to Acquire COPANs WASPLab, the Next Generation Full Laboratory Automation and Digital Bacteriology System
11. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... leading,developer of medical simulation systems, today announced an agreement ... and related,products. , Johnson & ... and,is one of the subsidiaries of Johnson & Johnson. ... will have exclusive rights to distribute,Simbionix,s line of advanced ...
... Newly Diagnosed Patients Receive a Drug Within One Year ... from Decision ResourcesWALTHAM, Mass., April 15 /PRNewswire/ ... leading research and advisory firms focusing on pharmaceutical and ... than 30 percent of their use of emerging oral ...
Cached Medicine Technology:Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 3
(Date:7/9/2014)... ITHACA, N.Y. Although feelings are personal and ... standard code that objectively represents emotions across different ... study by Cornell University neuroscientist Adam Anderson. , ... within the orbitofrontal cortex, an area of the ... neural code which captures an individual,s subjective feeling," ...
(Date:7/9/2014)... have been linked to an emerging fungal disease ... Institute for Mathematical and Biological Synthesis (NIMBioS) shows ... , In a series of mathematical models, researchers ... internal organs in frogs, could cause extinction of ... exposed to the virus every few years, a ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
(Date:7/9/2014)... , , , , , ... , , , , ... SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , ...
(Date:7/8/2014)... longevity and cardiovascular health as other healthy mature individuals, ... American Journal of Transplantation . The findings may provide ... transplant professionals caring for them. , Over the past ... years and older has become more common. Given the ... the removal of a kidney could make older donors ...
Breaking Medicine News(10 mins):Health News:Study cracks how the brain processes emotions 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:Study finds kidney donation safe for healthy older adults 2
... Survey finds children and their children are ... March 27 (HealthDay News) -- Alzheimer,s care in the ... suggests. , Three in five so-called "sandwich" caregivers who ... said their children help with care duties, ranging from ...
... Unveiling a Secure, Convenient Solution to Identify Blood ... BIO-key International,Inc. (OTC Bulletin Board: BKYI), a leader ... a proud sponsor at the spring,2008 AABB Conference ... association formerly known as the American Association of,Blood ...
... response to the growing,demand for solutions to ... United,States, a group of entrepreneurs has established ... consulting,firm with over 25 years experience in ... implement pharmaceutical care, and,"Inspire Pharmacists to Practice ...
... free dental screening, DALLAS, March 27 ... Computer Services, Inc. (ACS) will,sponsor free dental education ... 28. The event will be held for pupils ... in Dallas, starting at 9:00 a.m., The ...
... study ... participants, MINNEAPOLIS, ... Minnesota Cancer Center and ClearWay Minnesota(SM) found that,since the Freedom to ... significantly reduced exposure to a,tobacco-specific cancer causing chemical., The study ...
... Up, and Changes Lives, One Smile at ... a Time via Operation Smile Partnership, CINCINNATI, March 26 ... to host an upcoming award show,Samantha Harris knows firsthand the importance ... has partnered with Oral-B Satin,Floss to not only show people how ...
Cached Medicine News:Health News:With Alzheimer's, It Takes a Family 2Health News:With Alzheimer's, It Takes a Family 3Health News:BIO-key(R) to Sponsor and Exhibit at AABB Spring Conference 2Health News:BIO-key(R) to Sponsor and Exhibit at AABB Spring Conference 3Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:ACS Expands National Dental Outreach Program to Dallas 2Health News:U of M Study Provides First Scientific Evidence That the Freedom to Breathe Act is Creating Healthier Workplaces for Hospitality Employees 2Health News:U of M Study Provides First Scientific Evidence That the Freedom to Breathe Act is Creating Healthier Workplaces for Hospitality Employees 3Health News:Samantha Harris and Oral-B Satin Floss Partner to Share Smiles 2Health News:Samantha Harris and Oral-B Satin Floss Partner to Share Smiles 3
Toxoplasma IgM II ELISA....
HSV 1 & HSV 2 DFA Test....
Herpes Simplex Virus 2 IgG ELISA....
Herpes Simplex Virus 1 IgG ELISA....
Medicine Products: